The estimated Net Worth of Joseph S Zakrzewski is at least $1.78 Milión dollars as of 14 December 2021. Mr. Zakrzewski owns over 12,000 units of Amarin Corp stock worth over $115,963 and over the last 17 years he sold AMRN stock worth over $101,950. In addition, he makes $1,562,660 as Non-Executive Independent Director at Amarin Corp.
Joseph has made over 15 trades of the Amarin Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 12,000 units of AMRN stock worth $39,000 on 14 December 2021.
The largest trade he's ever made was exercising 300,000 units of Amarin Corp stock on 3 January 2020 worth over $1,020,000. On average, Joseph trades about 18,439 units every 80 days since 2008. As of 14 December 2021 he still owns at least 196,547 units of Amarin Corp stock.
You can see the complete history of Mr. Zakrzewski stock trades at the bottom of the page.
Joseph S. Zakrzewski serves as Non-Executive Independent Director of the Company. Mr. Zakrzewski joined Amarin as a non-executive director in January 2010. From November 2010 to December 2013, Mr. Zakrzewski served as Amarin’s Chief Executive Officer and Chairman of the Board of Directors. From May 2007 to May 2010, Mr. Zakrzewski served as President and Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics, and from January 2005 to May 2007, Mr. Zakrzewski served as the Chief Operating Officer of Reliant Pharmaceuticals. From 1988 to 2004, Mr. Zakrzewski served in a variety of positions at Eli Lilly and Company including as Vice President, Corporate Business Development from 2003 through 2004. In addition, Mr. Zakrzewski served as a Venture Partner with OrbiMed in 2010 and 2011. Mr. Zakrzewski currently serves on the board of directors of Acceleron Pharma and Sangamo Therapeutics as well as a number of privately held companies. Mr. Zakrzewski earned a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University as well as an M.B.A. in Finance from Indiana University. The Board believes that Mr. Zakrzewski should serve on our Board based on his knowledge of our Company gained from his former position as Chief Executive Officer and his substantial experience serving as an executive officer of other pharmaceutical companies, as well as Mr. Zakrzewski’s service as a member of boards of directors of other pharmaceutical companies. Mr. Zakrzewski’s contribution to the Company in the areas of operations and business development matters has been particularly helpful as the Company expands its commercialization efforts in light of the recently approved expanded label for Vascepa and as we continue our development efforts.
As the Non-Executive Independent Director of Amarin Corp, the total compensation of Joseph Zakrzewski at Amarin Corp is $1,562,660. There are 5 executives at Amarin Corp getting paid more, with John Thero having the highest compensation of $8,929,540.
Joseph Zakrzewski is 57, he's been the Non-Executive Independent Director of Amarin Corp since 2013. There are 8 older and 8 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.
Joseph's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BLVD., BRISBANE, CA, 94005.
Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum a David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Amarin Corp executives and other stock owners filed with the SEC include: